1
|
Retraction: Aberrant CCR4 Expression Is Involved in Tumor Invasion of Lymph Node-Negative Human Gastric Cancer. PLoS One 2020; 15:e0244287. [PMID: 33332463 PMCID: PMC7745966 DOI: 10.1371/journal.pone.0244287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
2
|
Hu J, Wang L, Guan C. MiR-532-5p Suppresses Migration and Invasion of Lung Cancer Cells Through Inhibiting CCR4. Cancer Biother Radiopharm 2020; 35:673-681. [PMID: 32228308 DOI: 10.1089/cbr.2019.3258] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Background: Studies showed that miR-532-5p suppresses proliferation and induces apoptosis of lung cancer (LC) cells; its role in LC is not fully understood. Therefore, this research aimed to reveal the effect and mechanism of miR-532-5p on migration and invasion of LC cells. Materials and Methods: The transfection efficiencies of miR-532-5p mimic, inhibitor, and overexpressed CCR4 were measured by quantitative real-time polymerase chain reaction (qRT-PCR). The relationships between miR-532-5p and CCR4 in A549 and SBC-5 cells were predicted by targetScan and verified by dual-luciferase reporter assay, Western blot, and qRT-PCR. Migration and invasion of cells transfected with miR-532-5p mimic, inhibitor, and CCR4 were determined by scratch test and transwell assay, respectively. The levels of epithelial-to-mesenchymal transition (EMT)-related proteins (E-cadherin (E-Cad)), N-catenin (N-Cad), and vimentin) in cells were measured by Western blot. Results: MiR-532-5p mimic suppressed migration and invasion, while miR-532-5p inhibitor promoted migration and invasion of cells. CCR4 was a downstream target of miR-532-5p and both its protein and mRNA expressions were inhibited by miR-532-5p mimic, but promoted by miR-532-5p inhibitor. CCR4 promoted migration, invasion, and EMT process, and such effects of CCR4 were reversed by miR-532-5p mimic. Conclusion: MiR-532-5p functioned as a cancer suppressor by negatively regulating CCR4 in LC cells, pointing to a potential protective mechanism of miR-532-5p to LC patients.
Collapse
Affiliation(s)
- Jingjing Hu
- Department of Respiratory Medicine, Hangzhou Dingqiao Hospital, Hangzhou, China
| | - Lu Wang
- Department of Emergency, Hangzhou Dingqiao Hospital, Hangzhou, China
| | - Caihong Guan
- Department of Respiratory, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China
| |
Collapse
|
3
|
Monette A, Morou A, Al-Banna NA, Rousseau L, Lattouf JB, Rahmati S, Tokar T, Routy JP, Cailhier JF, Kaufmann DE, Jurisica I, Lapointe R. Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets. J Clin Invest 2019; 129:2463-2479. [PMID: 30912767 DOI: 10.1172/jci125301] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Rationale Tumor infiltrating lymphocytes are widely associated with positive outcomes, yet carry key indicators of a systemic failed immune response against unresolved cancer. Cancer immunotherapies can reverse their tolerance phenotypes, while preserving tumor-reactivity and neoantigen-specificity shared with circulating immune cells. Objectives We performed comprehensive transcriptomic analyses to identify gene signatures common to circulating and tumor infiltrating lymphocytes in the context of clear cell renal cell carcinoma. Modulated genes also associated with disease outcome were validated in other cancer types. Findings Using bioinformatics, we identified practical diagnostic markers and actionable targets of the failed immune response. On circulating lymphocytes, three genes, LEF1, FASLG, and MMP9, could efficiently stratify patients from healthy control donors. From their associations with resistance to cancer immunotherapies and microbial infections, we uncovered not only pan-cancer, but pan-pathology failed immune response profiles. A prominent lymphocytic matrix metallopeptidase cell migration pathway, is central to a panoply of diseases and tumor immunogenicity, correlates with multi-cancer recurrence, and identifies a feasible, non-invasive approach to pan-pathology diagnoses. Conclusions The non-invasive differently expressed genes we have identified warrant future investigation towards the development of their potential in precision diagnostics and precision pan-disease immunotherapeutics.
Collapse
Affiliation(s)
- Anne Monette
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Montreal Cancer Institute, Montreal, Quebec, Canada.,Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.,Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
| | - Antigoni Morou
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Nadia A Al-Banna
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Montreal Cancer Institute, Montreal, Quebec, Canada.,Faculty of Medicine, McGill University, Montreal, Quebec, Canada.,Department of Basic Medical Sciences, College of Medicine, QU Health Cluster, Qatar University, Doha, Qatar
| | - Louise Rousseau
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada
| | - Jean-Baptiste Lattouf
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Montreal Cancer Institute, Montreal, Quebec, Canada.,Department of Surgery, University of Montreal, Montreal, Quebec, Canada
| | - Sara Rahmati
- Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Tomas Tokar
- Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada
| | - Jean-Pierre Routy
- Chronic Viral Illnesses Service and Division of Hematology, McGill University Health Centre, Montreal, Quebec, Canada
| | - Jean-François Cailhier
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Montreal Cancer Institute, Montreal, Quebec, Canada.,Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada.,Nephrology Division, Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Daniel E Kaufmann
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
| | - Igor Jurisica
- Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.,Department of Medical Biophysics and.,Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.,Institute of Neuroimmunology, Slovak Academy of Sciences, Slovak Republic
| | - Réjean Lapointe
- University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.,Montreal Cancer Institute, Montreal, Quebec, Canada.,Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Quebec, Canada
| |
Collapse
|
4
|
Zhao H, Bo Q, Wang W, Wang R, Li Y, Chen S, Xia Y, Wang W, Wang Y, Zhu K, Liu L, Cui J, Wang S, Liu Q, Wu Z, Guo H, Shi B. CCL17-CCR4 axis promotes metastasis via ERK/MMP13 pathway in bladder cancer. J Cell Biochem 2019; 120:1979-1989. [PMID: 30230587 DOI: 10.1002/jcb.27494] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2018] [Accepted: 07/25/2018] [Indexed: 01/24/2023]
Abstract
As an important chemokine receptor, the role of CCR4 in the progression of bladder cancer (BC) remains unknown. In this study, we have shown that CCR4 expression was upregulated in bladder carcinoma tissues compared with adjacent nontumor tissues. Kaplan-Meier survival analysis revealed that CCR4 expression was an independent prognostic risk factor in BC patients, and the addition of CCL17 induced CCR4 production and promoted migration and invasion of BC cells. In addition, CCR4 knockdown significantly attenuated the migratory and invasive capabilities of BC cells. Mechanistically, CCL17-CCR4 axis is involved in ERK1/2 signaling and could mediate the migration and invasion of BC cells by regulating MMP13 activation. This study suggests that CCR4 might represent a promising prognostic biomarker and a potential therapeutic option for BC.
Collapse
Affiliation(s)
- Hongda Zhao
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Qiyu Bo
- Department of First Operating Room, Qilu Hospital of Shandong University, Jinan, China
| | - Weifen Wang
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Rui Wang
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Yan Li
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Shouzhen Chen
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Yangyang Xia
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Wenfu Wang
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Yong Wang
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Kejia Zhu
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Lei Liu
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Jianfeng Cui
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Shuai Wang
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Qinggang Liu
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Zonglong Wu
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Hu Guo
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| | - Benkang Shi
- Department of Urology, Qilu Hospital of Shandong University, Jinan, China
| |
Collapse
|
5
|
Song Z, Zhao W, Cao D, Zhang J, Chen S. Elementary screening of lymph node metastatic-related genes in gastric cancer based on the co-expression network of messenger RNA, microRNA and long non-coding RNA. ACTA ACUST UNITED AC 2018; 51:e6685. [PMID: 29489999 PMCID: PMC5856436 DOI: 10.1590/1414-431x20176685] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2017] [Accepted: 11/17/2017] [Indexed: 01/26/2023]
Abstract
Gastric cancer (GC) is the fifth most common cancer and the third leading cause of
cancer-related deaths worldwide. The high mortality might be attributed to delay in
detection and is closely related to lymph node metastasis. Therefore, it is of great
importance to explore the mechanism of lymph node metastasis and find strategies to
block GC metastasis. Messenger RNA (mRNA), microRNA (miRNA) and long non-coding RNA
(lncRNA) expression data and clinical data were downloaded from The Cancer Genome
Atlas (TCGA) database. A total of 908 differentially expressed factors with variance
>0.5 including 542 genes, 42 miRNA, and 324 lncRNA were screened using significant
analysis microarray algorithm, and interaction networks were constructed using these
differentially expressed factors. Furthermore, we conducted functional modules
analysis in the network, and found that yellow and turquoise modules could separate
samples efficiently. The groups classified in the yellow and turquoise modules had a
significant difference in survival time, which was verified in another independent GC
mRNA dataset (GSE62254). The results suggested that differentially expressed factors
in the yellow and turquoise modules may participate in lymph node metastasis of GC
and could be applied as potential biomarkers or therapeutic targets for GC.
Collapse
Affiliation(s)
- Zhonghua Song
- Department of Oncology, Shandong University, Jinan, Shandong Province, China
| | - Wenhua Zhao
- Shandong Provincial Qianfoshan Hospital, Department of Oncology, Shandong University, Jinan, Shandong Province, China
| | - Danfeng Cao
- Shandong Provincial Qianfoshan Hospital, Department of Obstetrics, Shandong University, Jinan, Shandong Province, China
| | - Jinqing Zhang
- Department of Breast and Thyroid Surgery, Shandong University, Jinan, Shandong Province, China
| | - Shouhua Chen
- Shandong Provincial Qianfoshan Hospital, Department of General Surgery, Shandong University, Jinan, Shandong Province, China
| |
Collapse
|
6
|
Mytar B, Stec M, Szatanek R, Węglarczyk K, Szewczyk K, Szczepanik A, Drabik G, Baran J, Siedlar M, Baj-Krzyworzeka M. Characterization of human gastric adenocarcinoma cell lines established from peritoneal ascites. Oncol Lett 2018; 15:4849-4858. [PMID: 29552124 PMCID: PMC5840753 DOI: 10.3892/ol.2018.7995] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Accepted: 12/28/2017] [Indexed: 01/01/2023] Open
Abstract
The three cell lines, designated as gastric cancer (GC)1401, GC1415 and GC1436 were derived from peritoneal effusions from patients with gastric adenocarcinoma. Cell lines were established in tissue culture and in immunodeficient, non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. All cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum. These cell lines were grown as an adherent monolayer with doubling time ranging between 25 h (GC1436 cell line) and 30–34 h (GC1401 and GC1415, respectively). All cells showed morphological features of epithelial-like cells, forming sheets of polygonal cells. Chromosomal analysis showed that the modal numbers ranged from 52 (GC1401), 51–56 (GC1415) and 106 (GC1436). High heterogeneity, resulting from several structural and numerical chromosomal abnormalities were evident in all cell lines. The surface marker expression suggested a tumor origin of the cells, and indicated the intestinal phenotype of a GC (CD10+, MUC1). All three cell lines were tumorigenic but not metastatic, in vivo, in NOD/SCID mice. The lack of metastatic potential was suggested by the lack of aldehyde dehydrogenase 1A1 activity. In conclusion, these newly established GC cell lines widen the feasibility of the functional studies on biology of GC as well as drug testing for potential therapeutic purposes.
Collapse
Affiliation(s)
- Bożenna Mytar
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Małgorzata Stec
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Rafał Szatanek
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Kazimierz Węglarczyk
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Katarzyna Szewczyk
- Department of Medical Genetics Institute of Pediatrics, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Antoni Szczepanik
- First Department of General Gastrointestinal and Oncology Surgery, Jagiellonian University Medical College, 30-001 Krakow, Poland
| | - Grażyna Drabik
- Department of Transplantation, Institute of Pediatrics, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Jarek Baran
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Maciej Siedlar
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| | - Monika Baj-Krzyworzeka
- Department of Clinical Immunology, Jagiellonian University Medical College, 30-663 Krakow, Poland
| |
Collapse
|
7
|
Cheng X, Wu H, Jin ZJ, Ma D, Yuen S, Jing XQ, Shi MM, Shen BY, Peng CH, Zhao R, Qiu WH. Up-regulation of chemokine receptor CCR4 is associated with Human Hepatocellular Carcinoma malignant behavior. Sci Rep 2017; 7:12362. [PMID: 28959024 PMCID: PMC5620046 DOI: 10.1038/s41598-017-10267-4] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2016] [Accepted: 07/19/2017] [Indexed: 02/08/2023] Open
Abstract
Studies indicate that the chemokine receptor is responsible for poor prognosis of hepatocellular carcinoma (HCC) patients. In this study, we initially demonstrated that CCR4 is overexpressed in HCC specimens, and its elevation in HCC tissues positively correlates with tumor capsule breakthrough and vascular invasion. Although overexpression of CCR4 failed to influent proliferation of HCC cells in vitro apparently, the prominent acceleration on HCC tumor growth in vivo was remarkable. The underlying mechanism may be involved in neovascularization. Interestingly, different from effect on proliferation, CCR4 overexpression could trigger HCC metastasis both in vitro and in vivo also induced HCC cell epithelial-mesenchymal transition (EMT) as well. Then we identified matrix metalloproteinase 2 (MMP2) as a direct target of CCR4 which plays an important role in CCR4-mediated HCC cell invasion, which was up-regulated by ERK/AKT signaling. Positive correlation between CCR4 and MMP2 expression was also observed in HCC tissues. In conclusion, our study suggested that chemokine receptor CCR4 promotes HCC malignancy and facilitated HCC cell metastases via ERK/AKT/MMP2 pathway. These findings suggest that CCR4 may be a potential new diagnostic and prognostic marker in HCC, and targeting CCR4 may be a potential therapeutic option for blocking HCC metastasis.
Collapse
Affiliation(s)
- Xi Cheng
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Department of General Surgery, Ruijin North Hospital Shanghai Jiaotong University School of Medicine, Shanghai, 201800, China
| | - Huo Wu
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China
| | - Zhi-Jian Jin
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Ding Ma
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Stanley Yuen
- Biology chemistry major, University At Albany, New York, United States
| | - Xiao-Qian Jing
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Min-Min Shi
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Bai-Yong Shen
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
| | - Cheng-Hong Peng
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. .,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
| | - Ren Zhao
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. .,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. .,Department of General Surgery, Ruijin North Hospital Shanghai Jiaotong University School of Medicine, Shanghai, 201800, China.
| | - Wei-Hua Qiu
- Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. .,Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
| |
Collapse
|
8
|
Perera LP, Zhang M, Nakagawa M, Petrus MN, Maeda M, Kadin ME, Waldmann TA, Perera PY. Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies. Am J Hematol 2017; 92:892-901. [PMID: 28543380 DOI: 10.1002/ajh.24794] [Citation(s) in RCA: 68] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Revised: 05/11/2017] [Accepted: 05/15/2017] [Indexed: 02/06/2023]
Abstract
With the emerging success of treating CD19 expressing B cell malignancies with ex vivo modified, autologous T cells that express CD19-directed chimeric antigen receptors (CAR), there is intense interest in expanding this evolving technology to develop effective modalities to treat other malignancies including solid tumors. Exploiting this approach to develop a therapeutic modality for T cell malignancies for which the available regimens are neither curative, nor confer long term survival we generated a lentivirus-based CAR gene transfer system to target the chemokine receptor CCR4 that is over-expressed in a spectrum of T cell malignancies as well as in CD4+ CD25+ Foxp3+ T regulatory cells that accumulate in the tumor microenvironment constituting a barrier against anti-tumor immunity. Ex vivo modified, donor-derived T cells that expressed CCR4 directed CAR displayed antigen-dependent potent cytotoxicity against patient-derived cell lines representing ATL, CTCL, ALCL and a subset of HDL. Furthermore, these CAR T cells also eradicated leukemia in a mouse xenograft model of ATL illustrating the potential utility of this modality in the treatment of a wide spectrum of T cell malignancies.
Collapse
Affiliation(s)
- Liyanage P. Perera
- Lymphoid Malignancies Branch, National Cancer Institute; Bethesda Maryland 20892-1374 USA
| | - Meili Zhang
- Lymphoid Malignancies Branch, National Cancer Institute; Bethesda Maryland 20892-1374 USA
| | - Masao Nakagawa
- Lymphoid Malignancies Branch, National Cancer Institute; Bethesda Maryland 20892-1374 USA
| | - Michael N. Petrus
- Lymphoid Malignancies Branch, National Cancer Institute; Bethesda Maryland 20892-1374 USA
| | - Michiyuki Maeda
- Institute for Virus Research, Kyoto University; Sakyo-ku Kyoto Japan
| | - Marshall E. Kadin
- Boston University School of Medicine, Department of Dermatology and Skin Surgery; Roger Williams Medical Center; Providence Rhode 02908
| | - Thomas A. Waldmann
- Lymphoid Malignancies Branch, National Cancer Institute; Bethesda Maryland 20892-1374 USA
| | - Pin-Yu Perera
- Veterans Affairs Medical Center; Washington D.C. 20422 USA
| |
Collapse
|
9
|
Kircher DA, Silvis MR, Cho JH, Holmen SL. Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. Int J Mol Sci 2016; 17:E1468. [PMID: 27598148 PMCID: PMC5037746 DOI: 10.3390/ijms17091468] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2016] [Revised: 08/02/2016] [Accepted: 08/26/2016] [Indexed: 12/15/2022] Open
Abstract
The development of brain metastases in patients with advanced stage melanoma is common, but the molecular mechanisms responsible for their development are poorly understood. Melanoma brain metastases cause significant morbidity and mortality and confer a poor prognosis; traditional therapies including whole brain radiation, stereotactic radiotherapy, or chemotherapy yield only modest increases in overall survival (OS) for these patients. While recently approved therapies have significantly improved OS in melanoma patients, only a small number of studies have investigated their efficacy in patients with brain metastases. Preliminary data suggest that some responses have been observed in intracranial lesions, which has sparked new clinical trials designed to evaluate the efficacy in melanoma patients with brain metastases. Simultaneously, recent advances in our understanding of the mechanisms of melanoma cell dissemination to the brain have revealed novel and potentially therapeutic targets. In this review, we provide an overview of newly discovered mechanisms of melanoma spread to the brain, discuss preclinical models that are being used to further our understanding of this deadly disease and provide an update of the current clinical trials for melanoma patients with brain metastases.
Collapse
Affiliation(s)
- David A Kircher
- Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
| | - Mark R Silvis
- Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
| | - Joseph H Cho
- Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
| | - Sheri L Holmen
- Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
- Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
- Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.
| |
Collapse
|
10
|
Liu LB, Xie F, Chang KK, Shang WQ, Meng YH, Yu JJ, Li H, Sun Q, Yuan MM, Jin LP, Li DJ, Li MQ. Chemokine CCL17 induced by hypoxia promotes the proliferation of cervical cancer cell. Am J Cancer Res 2015; 5:3072-3084. [PMID: 26693060 PMCID: PMC4656731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2015] [Accepted: 06/18/2015] [Indexed: 06/05/2023] Open
Abstract
Cervical cancer is often associated with hypoxia and many kinds of chemokines. But the relationship and role of hypoxia and Chemokine (C-C motif) ligand 17 (CCL17) in cervical cancer are still unknown. Here, we found that CCL17 was high expressed in cervical cancer. HeLa and SiHa cells could secrete CCL17 in a time-dependent manner. Hypoxia increased expression of CCL17 receptor (CCR4) on HeLa and SiHa cells. Treatment with recombination human CCL17 (rhCCL17) led to an elevation of cell proliferation in HeLa and SiHa cells in a dose-dependent manner. In contrast, blocking CCL17 with anti-human CCL17 neutralizing antibody (α-CCL17) played an oppose effect. However, rhCCL17 had no effect on apoptosis in cervical cancer cells. Further analysis showed that hypoxia promoted the proliferation of HeLa and SiHa cells, and these effects could be reversed by α-CCL17. Stimulation with the inhibitor for c-Jun N-terminal kinase (JNK) or signal transducers and activator of transcription 5 (STAT5) signal pathway not only directly decreased the proliferation of HeLa and SiHa cells, but also abrogated the stimulatory effect of rhCCL17 on the proliferation of HeLa and SiHa cells. These results suggest that a high level of CCL17 in cervical cancer lesions is an important regulator in the proliferation of cervical cancer cells through JNK and STAT5 signaling pathways. In this process, hypoxia magnifies this effect by up-regulating CCR4 expression and strengthening the interaction of CCL17/CCR4.
Collapse
Affiliation(s)
- Li-Bing Liu
- Department of Obstetrics and Gynecology, Changzhou NO.2 People’s Hospital, Nanjing Medical UniversityChangzhou 213003, Jiangsu Province, The People’s Republic of China
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Feng Xie
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
- Medical Center of Diagnosis and Treatment for Cervical Diseases, Hospital of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Kai-Kai Chang
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Wen-Qing Shang
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Yu-Han Meng
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Jia-Jun Yu
- Department of Obstetrics and Gynecology, Changzhou NO.2 People’s Hospital, Nanjing Medical UniversityChangzhou 213003, Jiangsu Province, The People’s Republic of China
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Hui Li
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Qian Sun
- Yerkes National Primate Research Center, Emory UniversityAtlanta, GA 30329, USA
| | - Min-Min Yuan
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Li-Ping Jin
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
- Shanghai Key Laboratory of Female Reproductive Endocrine Related DiseasesShanghai 200011, The People’s Republic of China
| | - Da-Jin Li
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
| | - Ming-Qing Li
- Laboratory for Reproductive Immunology, Hospital and Institute of Obstetrics and Gynecology, Fudan UniversityShanghai 200011, The People’s Republic of China
- Shanghai Key Laboratory of Female Reproductive Endocrine Related DiseasesShanghai 200011, The People’s Republic of China
| |
Collapse
|
11
|
Zhao J, Yang C, Guo S, Wu Y. GM130 regulates epithelial-to-mesenchymal transition and invasion of gastric cancer cells via snail. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2015; 8:10784-10791. [PMID: 26617790 PMCID: PMC4637605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 08/20/2015] [Indexed: 06/05/2023]
Abstract
Gastric cancer is one of the most common causes of digestive tract tumor. Despite of recent advances in surgical techniques and development of adjuvant therapy, the underlying mechanisms of gastric cancer remain poorly understood and relevant insight into novel treatment strategies using gene target remains incomplete. Recently, several studies report that epithelial to mesenchymal transition (EMT) is a crucial process for the invasion and metastasis of epithelial tumors; however, the molecular mechanisms underlying this transition are unknown. As a cis-Golgi matrix protein, GM130 plays an important role in cell cycle progression and transport of protein in the secretory pathway. In this study, we found that GM130 expression has a positive correlation with the pathological differentiation and tumor node metastasis (TNM) stage of gastric cancer. High GM130 expression levels also predict shorter overall survival of gastric cancer patients. RNA interference-mediated knockdown of GM130 expression increased epithelial marker (E-cadherin) and decreased mesenchymal marker (N-cadherin and vimentin) expression in gastric cancer cells, suppressing cell invasion, and tumor formation. Furthermore, we found that GM130 upregulated expression of the key EMT regulator Snail (SNAI1), which mediated EMT activation and cell invasion by GM130. Taken together, our study indicates GM130 may be a promising therapeutic biomarker for gastric cancer.
Collapse
Affiliation(s)
- Jianquan Zhao
- Department of Cardiology, Bayannaoer City HospitalInner Mongolia, China
| | - Chun Yang
- Department of Medical Cosmetology Bayannaoer City HospitalInner Mongolia, China
| | - Shujun Guo
- Department of Cardiology, Bayannaoer City HospitalInner Mongolia, China
| | - Yonggang Wu
- Department of Orthopedics, Bayannaoer City HospitalInner Mongolia, China
| |
Collapse
|